Illumina Misses Q1 Expectations, Posts Preliminary Revenue Growth of 6 Percent | GenomeWeb

NEW YORK (GenomeWeb) – Illumina's estimated first quarter revenues grew 6 percent over the first quarter of 2016, falling short of expectations, the firm said Monday after the close of market and in advance of its first quarter earnings call.

Illumina estimated its Q1 revenues to be around $572 million compared to $539 million in the year ago quarter. Analysts, on average, had predicted that Illumina's Q1 revenues would be $596.3 million.

In response to the announcement, the firm's shares plummeted 25 percent to $133.49 in early Tuesday trade on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.

Mar
16
Sponsored by
Agilent Technologies

This online seminar will discuss how improvements on the front end and back end of the sequencing workflow can lead to better RNA-seq results.

Mar
28

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment.